New Data Highlights Advantages of Accuray’s CyberKnife for Treating Liver Metastasis
Researchers presented more than 50 studies highlighting the benefits of Accuray’s CyberKnife System at the 36th Annual European Society for Radiotherapy and Oncology (ESTRO) Meeting in Vienna.
One study in particular, “Unresectable hepatic oligorecurrence SBRT of 55 lesion: Adequate dose coverage improves local control,” showed that CyberKnife treatment with stereotactic body radiation therapy (SBRT) may benefit patients with metastatic disease progression involving the liver.
The study, conducted by Hungary’s University of Kapsovar, was designed to assess local control (LC), survival and toxicity in patients with recurrent liver metastases treated with SBRT.
The study followed 42 patients treated between 2010 and 2015 (with a median follow-up of 18.9 months) who had MRI-confirmed oligorecurrent liver metastases and were ineligible for surgery. The follow-ups showed local control of 81.3 percent at one year and 76.3 percent at two years. Overall survival was 86.9 percent at one year and 78.3 percent at two years, which the researchers described as favorable.
The study also provided data on the effective radiation dose required to significantly improve local control (45 Gy, or 43 Gy when accounting for uncertainties in planning or treatment delivery, to reach at least 95 percent of all tumors).
According to researchers, the data and study support a potential shift towards using SBRT to treat unresectable liver metastases.
The CyberKnife System is an automated radiation delivery system designed to deliver precise radiation therapy to target cancer while sparing surrounding healthy tissue and structures. SBRT involves a single high-dose radiation treatment or a few fractioned radiation treatments, delivered with high precision using a coordinate system.
“I am proud to see that the unique capabilities of our radiation therapy delivery systems are enabling clinicians to develop innovative approaches for delivering radiation treatments which make a real difference in their patients’ lives,” Fabienne Hirigoyenberry, Accuray’s vice-president of global medical and scientific affairs, said in a press release. ”Since 1994 when the first patient was treated with the CyberKnife System, it has set the bar for delivering precise radiation treatments while avoiding healthy tissue.”
